Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 881

1.

Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis.

Alvaro D, Macarri G, Mancino MG, Marzioni M, Bragazzi M, Onori P, Corradini SG, Invernizzi P, Franchitto A, Attili AF, Gaudio E, Benedetti A.

Ann Intern Med. 2007 Oct 2;147(7):451-9. Erratum in: Ann Intern Med. 2007 Nov 6;147(9):676.

PMID:
17909206
2.

The value of biliary fibronectin for diagnosis of cholangiocarcinoma.

Chen CY, Lin XZ, Tsao HC, Shiesh SC.

Hepatogastroenterology. 2003 Jul-Aug;50(52):924-7.

PMID:
12845951
3.

Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Malignant and Benign Biliary Obstructions.

Abdel-Razik A, ElMahdy Y, Hanafy EE, Elhelaly R, Elzehery R, M Tawfik A, Eldars W.

Am J Med Sci. 2016 Mar;351(3):259-64. doi: 10.1016/j.amjms.2015.12.013.

PMID:
26992254
4.

Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.

Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, Pitt HA.

Am J Surg. 1996 Jan;171(1):147-52; discussion 152-3.

PMID:
8554130
5.

Vascular endothelial growth factor levels in bile distinguishes pancreatic cancer from other etiologies of biliary stricture: a pilot study.

Navaneethan U, Gutierrez NG, Jegadeesan R, Venkatesh PG, Poptic E, Liu X, Sanaka MR, Jang S, Vargo JJ, Parsi MA.

Dig Dis Sci. 2013 Oct;58(10):2986-92. doi: 10.1007/s10620-013-2764-0. Epub 2013 Jul 5.

PMID:
23828141
6.

[Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].

Trapeznikova MF, Shibaeva AN, Ianshin AA, Urenkov SB, Mironova OS, Kazantseva IA, Kushlinskiĭ NE.

Urologiia. 2004 Jan-Feb;(1):17-21. Russian.

PMID:
15022438
7.

Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.

Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC.

Hepatology. 2006 Sep;44(3):658-66.

PMID:
16941699
9.

Serum and bile biomarkers for cholangiocarcinoma.

Alvaro D.

Curr Opin Gastroenterol. 2009 May;25(3):279-84. Review.

PMID:
19396965
10.

Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.

Ince AT, Yıldız K, Baysal B, Danalıoğlu A, Kocaman O, Tozlu M, Gangarapu V, Sarbay Kemik A, Uysal Ö, Şentürk H.

Turk J Gastroenterol. 2014 Apr;25(2):162-9. doi: 10.5152/tjg.2014.6056.

11.

Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.

Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A.

Cancer. 2004 Oct 1;101(7):1609-15.

12.

A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.

Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI.

Am J Gastroenterol. 1999 Jul;94(7):1941-6.

PMID:
10406263
13.

Increased intercellular adhesion molecule-1 serum concentration in cholestasis.

Polzien F, Ramadori G.

J Hepatol. 1996 Dec;25(6):877-86.

PMID:
9007716
14.

Bile levels of carcino-embryonic antigen in patients with hepatopancreatobiliary disease.

Buffet C, Fourré C, Altman C, Prat F, Fritsch J, Choury A, Briantais MJ, Desgrez A, Etienne JP.

Eur J Gastroenterol Hepatol. 1996 Feb;8(2):131-4.

PMID:
8723416
15.

Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis.

Chen CY, Tsai WL, Wu HC, Syu MJ, Wu CC, Shiesh SC.

Clin Chim Acta. 2008 Apr;390(1-2):82-9. doi: 10.1016/j.cca.2008.01.011. Epub 2008 Jan 16.

PMID:
18252202
16.

[MR cholangiopancreatography: technique, indications and clinical results].

Pavone P, Laghi A, Panebianco V, Catalano C, Passariello R.

Radiol Med. 1997 Dec;94(6):632-41. Italian.

PMID:
9524602
17.

EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study.

Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, Cameron R, Hashimoto Y, Shah JN.

Gastrointest Endosc. 2014 Jul;80(1):97-104. doi: 10.1016/j.gie.2013.12.031. Epub 2014 Feb 19.

PMID:
24559784
18.

The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.

Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A.

Dig Dis Sci. 2011 Aug;56(8):2491-6. doi: 10.1007/s10620-011-1709-8. Epub 2011 Apr 23.

PMID:
21516323
19.

Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.

Ahrendt SA, Pitt HA, Nakeeb A, Klein AS, Lillemoe KD, Kalloo AN, Cameron JL.

J Gastrointest Surg. 1999 Jul-Aug;3(4):357-67; discussion 367-8.

PMID:
10482687
20.

Feasibility and complications of endoscopic biliary drainage in patients with malignant biliary obstruction at King Chulalongkorn Memorial Hospital.

Rerknimitr R, Attasaranya S, Kladchareon N, Mahachai V, Kullavanijaya P.

J Med Assoc Thai. 2002 Jun;85 Suppl 1:S48-53.

PMID:
12188451

Supplemental Content

Support Center